Trending/Research
Carfilzomib is not superior to Bortezomib in delaying multiple myeloma progression after initial treatment
ROCHESTER, Minn. ― Carfilzomib, a proteasome inhibitor used in combination with Lenalidomide, an immune modulating drug, is not superior to Bortezomib, Lenalidomide and Dexamethasone, in the initial treatment of multiple myeloma according…
May 21, 2020
May 13, 2020
Special Topics
Sign up
Social Media Network
A network for digital healthcare communicators
Mayo Clinic Connect
An online patient support community